Antihyperglycemic

20(R)-Protopanaxatriol
Catalog No: CFN99980

20(R)-Protopanaxatriol shows anti-hyperglycaemic, and anti-cancer activities.Protopanaxatriol has inhibitory effects on the enzyme catalytic activities of cyclooxygenases-1 and -2 (COX-1 and -2).

Guaijaverin
Catalog No: CFN98211

Guaijaverin is a urease inhibitor, it (IC(50)=0.18 microM) shows an inhibitory effect on rat lens aldose reductase. Guaijaverin has antioxidant, hypoglycemic activity and inhibitory capacity against free fatty acid release.It demonstrates high potential antiplaque agent by inhibiting the growth of the Strep. Mutans.

3,8-Di-O-methylellagic acid
Catalog No: CFN98217

3,3'-Di-O-methylellagic acid reveals moderate antibacterial activity, it also shows strong DPPH radical scavenging activities with SC50 of 123.3 ug/mL. It has a lower capacity of stimulating murine peritoneal macrophages to release nitric oxide and tumoural-alpha necrose factor. 3,3'-Di-O-methylellagic acid may be a useful as pharmacological agent for the treatment of neurodegenerative diseases.

Cimiracemoside C
Catalog No: CFN98288

The Cimicifuga racemosa extract Ze 450 and some of its components (23-epi-26-deoxyactein, protopine and cimiracemoside C) can reduce significantly body weight, plasma glucose, improve glucose metabolism and insulin sensitivity in diabetic ob/ob mice; suggests that part of the effects may be related to AMPK activation.Ze 450 may have utility in the treatment of type 2 diabetes.

Timosaponin A3
Catalog No: CFN98151

Timosaponin A3 triggers liver injury through inducing ROS generation and suppressing the expression of BA transporters, it has selectively cytotoxic for cancer versus normal cells. Timosaponin A3 can inhibit nuclear factor-kB and p38 signaling in TNF-a stimulated BV2 microglia cells, it has the therapeutic potential for various neurodegenerative diseases caused by inflammation. Timosaponin A3 also has application for reducing blood sugar and treating type-B diabete.